IMMUNOQUEST THERAPEUTICS AS
Signals
- Negativ egenkapital 2024 Bokført egenkapital er negativ (−721k kr).
- Driftsunderskudd 2024 Siste driftsresultat er negativt (−718k kr).
- Ingen revisor Selskapet har ingen registrert revisor. Vanlig for små AS som har valgt bort revisjon, men verdt å merke seg.
- Nylig endring 2026-02-03 Aksjekapital registrert 2026-02-03.
IMMUNOQUEST THERAPEUTICS AS is registered as a limited company in Oslo, Oslo with organisation number 931892266. The business is classified under research and experimental development on natural sciences and engineering (NACE 72.100). The company was incorporated in 2023. Registered share capital is NOK 43,000, divided into 43019 shares. The company's stated purpose is: “Forskning og utvikling av kreftbehandling.”. The most recent filed accounts, for the 2024 financial year, show NOK 0 in revenue and NOK −718,000 in operating profit.
Key figures · 2024
Financial health · 2024
Solidity capped at Weak because equity is below NOK 100,000.
Who owns IMMUNOQUEST THERAPEUTICS AS?
IMMUNOQUEST THERAPEUTICS AS has 3 registered shareholders:
- INVEN2 AS 60.0%
- JON AMUND KYTE 20.0%
- THE N AS 20.0%
Frequently asked questions about IMMUNOQUEST THERAPEUTICS AS
Who owns IMMUNOQUEST THERAPEUTICS AS?
INVEN2 AS is the largest registered owner, with 60.0%.
What is the revenue of IMMUNOQUEST THERAPEUTICS AS?
IMMUNOQUEST THERAPEUTICS AS had revenue of NOK 0 in 2024.
Where is IMMUNOQUEST THERAPEUTICS AS based?
IMMUNOQUEST THERAPEUTICS AS has its business address in Oslo.
Source: Biztrac.no · Data from the Brønnøysund Register Centre and the Norwegian Tax Administration · Last updated 15.06.2026.